LEADER 01518nam  2200469   450 
001 9910693974103321
005 20221024215037.0
035   $a(CKB)3450000000002507
035   $a(NjHacI)993450000000002507
035   $a(OCoLC)57396979
035 9 $aocm57396979
035   $a(OCoLC)993450000000002507
035   $a(EXLCZ)993450000000002507
100   $a20221024d2004      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMelatonin for treatment of sleep disorders /$fNina Buscemi [and nine others]
210  1$aRockville (MD) :$cAgency for Healthcare Research and Quality (US),$d[2004]
210  4$dİ2004
215   $a1 online resource (153 pages) $cillustrations
225 1 $aEvidence report/technology assessment. Summary ;$vno. 108
225 1 $aAHRQ pub. ;$vno. 05-E002-1
300   $aTitle from title screen (viewed on Jan. 10, 2005).
300   $a"November 2004."
320   $aIncludes bibliographical references.
606   $aSleep disorders
606   $aMelatonin
615  0$aSleep disorders.
615  0$aMelatonin.
676   $a616.8498
700   $aBuscemi$b Nina
701   $aBuscemi$b N$01383589
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910693974103321
996   $aMelatonin for treatment of sleep disorders$93428584
997   $aUNINA